Potential Impact of Treatment with Inotuzumab Ozogamicin on Chimeric Antigen Receptor T-Cell Therapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia

被引：2
|
作者：
Ceolin, Valeria [1 ,2 ]
Brivio, Erica [2 ,3 ]
Rheingold, Susan R. [4 ]
Leahy, Allison Barz [5 ]
Vormoor, Britta Julia [2 ]
O'Brien, Maureen M. [6 ]
Rubinstein, Jeremy [7 ]
Kalwak, Krzysztof [8 ]
De Moerloose, Barbara [9 ]
Jacoby, Elad [10 ,11 ]
Bader, Peter [12 ]
Fuster, Jose L. [13 ]
Locatelli, Franco [14 ]
Hoogerbrugge, Peter [2 ]
Calkoen, Friso [2 ]
Zwaan, Christian M. [2 ,3 ]
机构：
[1] Univ Turin, Regina Margherita Childrens Hosp, Dept Pediat Oncol Hematol, Turin, Italy
[2] Princess Maxima Ctr Pediat Oncol, Utrecht, Netherlands
[3] Erasmus Univ, MC Sophia Childrens Hosp, Rotterdam, Netherlands
[4] Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med, Div Pediat Oncol, Philadelphia, PA USA
[5] Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA USA
[6] Cincinnati Childrens Hosp, Med Ctr, Cincinnati, OH USA
[7] Univ Cincinnati, Canc & Blood Dis Inst, Cincinnati Childrens Hosp, Sch Med,Med Ctr, Cincinnati, OH USA
[8] Wroclaw Med Univ, Dept Pediat Hematol Oncol & Bone Marrow Transplan, Wroclaw, Poland
[9] Ghent Univ Hosp, Dept Pediat Oncol Hematol & Stem Cell Transplanta, Ghent, Belgium
[10] Edmond & Lily Safra Childrens Hosp, Div Pediat Hematol Oncol & BMT, Sheba Med Ctr, Tel Aviv, Israel
[11] Sackler Fac Med, Tel Aviv, Israel
[12] Goethe Univ, Univ Hosp Frankfurt, Dept Pediat Oncol Hematol, Clin Children & Youth Med, Frankfurt, Germany
[13] Hosp Valdecilla, Dept Hematol, Pediat Hematol Unit, Santander, Spain
[14] Sapienza Univ Rome, Bambino Gesu Childrens Hosp, Dept Hematol Oncol & Cell & Gene Therapy, Rome, Italy
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-146556
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3824
引用
收藏
页码：3824 / +
页数：5
相关论文
共 50 条
  • [1] Impact of Treatment with Inotuzumab Ozogamicin before or after Chimeric Antigen Receptor T-Cell Therapy in Children with Relapsed/Refractory Acute Lymphoblastic Leukemia
    Rheingold, Susan R.
    Ji, Lingyun
    Gore, Lia
    Xu, Xinxin
    Bhojwani, Deepa
    Shah, Nirali N.
    Raetz, Elizabeth A.
    Loh, Mignon L.
    O'Brien, Maureen M.
    BLOOD, 2023, 142
  • [2] Outcome of chimeric antigen receptor T-cell therapy following treatment with inotuzumab ozogamicin in children with relapsed or refractory acute lymphoblastic leukemia
    Valeria Ceolin
    Erica Brivio
    Harm van Tinteren
    Susan R. Rheingold
    Allison Leahy
    Britta Vormoor
    Maureen M. O’Brien
    Jeremy D. Rubinstein
    Krzysztof Kalwak
    Barbara De Moerloose
    Elad Jacoby
    Peter Bader
    Mónica López-Duarte
    Bianca F. Goemans
    Franco Locatelli
    Peter Hoogerbrugge
    Friso G. Calkoen
    Christian Michel Zwaan
    Leukemia, 2023, 37 : 53 - 60
  • [3] Outcome of chimeric antigen receptor T-cell therapy following treatment with inotuzumab ozogamicin in children with relapsed or refractory acute lymphoblastic leukemia
    Ceolin, Valeria
    Brivio, Erica
    van Tinteren, Harm
    Rheingold, Susan R.
    Leahy, Allison
    Vormoor, Britta
    O'Brien, Maureen M.
    Rubinstein, Jeremy D.
    Kalwak, Krzysztof
    De Moerloose, Barbara
    Jacoby, Elad
    Bader, Peter
    Lopez-Duarte, Monica
    Goemans, Bianca F.
    Locatelli, Franco
    Hoogerbrugge, Peter
    Calkoen, Friso G.
    Zwaan, Christian Michel
    LEUKEMIA, 2023, 37 (01) : 53 - 60
  • [4] Inotuzumab ozogamicin in the treatment of relapsed/refractory acute B cell lymphoblastic leukemia
    Uy, Natalie
    Nadeau, Michelle
    Stahl, Maximilian
    Zeidan, Amer M.
    JOURNAL OF BLOOD MEDICINE, 2018, 9 : 67 - 74
  • [5] Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia
    George, Binsah
    Kantarjian, Hagop
    Jabbour, Elias
    Jain, Nitin
    IMMUNOTHERAPY, 2016, 8 (02) : 135 - 143
  • [6] Chimeric antigen receptor T-cell therapy for T-cell acute lymphoblastic leukemia
    Oh, Bernice L. Z.
    Vinanica, Natasha
    Wong, Desmond M. H.
    Campana, Dario
    HAEMATOLOGICA, 2024, 109 (06) : 1677 - 1688
  • [7] Cost-effectiveness of chimeric antigen receptor T-cell therapy in pediatric relapsed/refractory acute lymphoblastic leukemia.
    Sarkar, Reith
    Gloude, Nicholas Joseph
    Murphy, James Don
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [8] Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia
    Deepa Bhojwani
    Richard Sposto
    Nirali N. Shah
    Vilmarie Rodriguez
    Constance Yuan
    Maryalice Stetler-Stevenson
    Maureen M. O’Brien
    Jennifer L. McNeer
    Amrana Quereshi
    Aurelie Cabannes
    Paul Schlegel
    Claudia Rossig
    Luciano Dalla-Pozza
    Keith August
    Sarah Alexander
    Jean-Pierre Bourquin
    Michel Zwaan
    Elizabeth A. Raetz
    Mignon L. Loh
    Susan R. Rheingold
    Leukemia, 2019, 33 : 884 - 892
  • [9] Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Pediatric B-Cell Acute Lymphoblastic Leukemia
    Lin, John K.
    Lerman, Benjamin J.
    Barnes, James I.
    Boursiquot, Brian C.
    Tan, Yuan Jin
    Robinson, Alex Q. L.
    Davis, Kara L.
    Owens, Douglas K.
    Goldhaber-Fiebert, Jeremy D.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (32) : 3192 - +
  • [10] BUDGET IMPACT ANALYSIS OF INOTUZUMAB OZOGAMICIN FOR THE TREATMENT OF ADULTS WITH RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA IN COLOMBIA
    Arciniegas, J.
    Sossa, C.
    Nakandakari, M. L.
    Reyes Sanchez, J. M.
    VALUE IN HEALTH, 2023, 26 (06) : S88 - S88
12345